1. Introduction {#sec1-ijms-17-01597}
===============

Non-small cell lung cancer (NSCLC), one of the most common and highly frequent malignancies, is a leading cause of cancer-related death in the population \[[@B1-ijms-17-01597]\]. Risk factors associated with environment and lifestyle include family history of lung cancer, history of pulmonary diseases, nutrition, air pollution, cigarette smoke, and exposure to radiation, asbestos and radon. Furthermore, recent epidemiological studies have shown that exposure to solar radiation (in particular ultraviolet B (UVB) radiation) and vitamin D intake is connected with decreased incidence of many cancers including lung, breast, prostate and colon cancer \[[@B2-ijms-17-01597],[@B3-ijms-17-01597],[@B4-ijms-17-01597],[@B5-ijms-17-01597],[@B6-ijms-17-01597]\]. The mortality of lung cancer is lowest during the autumn and summer months, which are associated with the highest vitamin D levels in a year \[[@B7-ijms-17-01597]\]. The vitamin D~3~ and vitamin D~2~, two natural primary forms of vitamin D, are endogenously generated from sun exposure or ingestion of food or supplements \[[@B8-ijms-17-01597]\]. Vitamin D is hydroxylated at 25 position to 25-hydroxy vitamin D \[25(OH)D\] and further hydroxylated by 1α-hydroxylase (encoded by *CYP27B1*) in the kidney to 1,25-dihydroxy vitamin D \[1,25(OH)2D\]. The concentrations of 25(OH)D are usually 100 to 1000-fold higher than the ones of 1,25(OH)~2~D \[[@B9-ijms-17-01597]\]. It is released into the blood circulation in the gut and then passively reabsorbed in the kidneys through mechanisms mediated by the vitamin D receptor (encoded by *VDR* gene), as shown in [Figure 1](#ijms-17-01597-f001){ref-type="fig"}.

Finally, 24-hydroxylase (encoded by *CYP24A1*) degrades both 1,25(OH)~2~D and 25(OH)D into non-active forms. *VDR*, the superfamily of transacting transcriptional regulatory factors, adjusts to several gene transcriptions, including cell apoptosis, pro-oncogenes, immunomodulation, differentiation, and tumor-suppressor genes \[[@B9-ijms-17-01597],[@B10-ijms-17-01597]\]. The vitamin D-binding protein (encoded by the *group-specific component*, *GC* gene) mainly promotes transportation of vitamin D metabolites \[[@B11-ijms-17-01597]\]. Laboratory studies showed that high 1,25(OH)~2~D levels can inhibit differentiation and proliferation in human lung cancer cell lines \[[@B12-ijms-17-01597]\], and circulating 25(OH)D level may predict early-stage NSCLC patients' survival \[[@B13-ijms-17-01597],[@B14-ijms-17-01597]\]. Vitamin D-related genes have highly polymorphic genotypes in different human populations. Moreover, as a subgroup, they have been widely analyzed in multitudinous cancer-related studies \[[@B15-ijms-17-01597],[@B16-ijms-17-01597]\]. However, in previously conducted studies, genetic variation in *VDR* has not been systematically analyzed with regard to NSCLC, and very limited data are available on *CYP27B1* and *CYP24A1* polymorphisms \[[@B17-ijms-17-01597],[@B18-ijms-17-01597]\]. In addition, epidemiological and clinical studies inspecting the associations between NSCLC risk and vitamin D status are limited in number and inconclusive \[[@B19-ijms-17-01597],[@B20-ijms-17-01597]\]. To investigate the associations between vitamin D, genetic polymorphisms in the vitamin D metabolism pathway, cigarette smoke and NSCLC risk, we conducted a case-control study and utilized the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique to evaluate the single-nucleotide polymorphisms (SNPs), which were located in the protein coding and promoter regions *VDR*, *CYP24A1*, *CYP27B1* and *GC* genes. We then evaluated whether the vitamin D status was connected with the NSCLC risk by a radioimmunoassay method. We additionally examined the deficiency of vitamin D combined with smoking through questionnaire information.

2. Results {#sec2-ijms-17-01597}
==========

2.1. Descriptive Characteristics {#sec2dot1-ijms-17-01597}
--------------------------------

Characteristics of controls and NSCLC cases are displayed in [Table 1](#ijms-17-01597-t001){ref-type="table"}. There were no statistically significant differences in the allocation of age, gender, marriage status, body mass index (BMI), education, and leisure physical activity between cases and controls. However, the significant differences were observed in smoking status and family history of cancer between cases and controls (17.8% vs. 9.5%, *p* \< 0.001). As expected, more NSCLC cases were smokers compared to the controls (70.0% vs. 48.5%, *p* \< 0.001).

2.2. Relationship between SNPs, Smoking and NSCLC Risk {#sec2dot2-ijms-17-01597}
------------------------------------------------------

Fifteen SNPs in four genes were examined in our study. The odds ratios (ORs) and 95% confidence intervals (CIs) for association between smoking and NSCLC were stratified by 25(OH)D, as shown in [Table 2](#ijms-17-01597-t002){ref-type="table"}. The results showed that smoking was related to increased NSCLC risk, regardless of the concentration of plasma 25(OH)D \<20 ng/mL or ≥20 ng/mL (OR = 2.74, 95% CI 1.97--3.01, *p* \< 0.001 in \<20 ng/mL; OR = 2.48, 95% CI 2.05--2.97, *p* \< 0.001 in ≥20 ng/mL, respectively), in a statistically significant manner. The OR and 95% CIs for associations between vitamin D-related genotypes and NSCLC risk are shown in [Table 3](#ijms-17-01597-t003){ref-type="table"}. For *CYP24A1* polymorphisms, we found that rs6068816 was significant related to reduction of NSCLC risk (TT vs. CC, OR = 0.31, 95% CI 0.21--0.47; *p* \< 0.001). No statistically significant increased risk of NSCLC was observed in rs2181874 (AA vs. GG, OR = 1.40, 95% CI 0.85--1.92, *p* = 0.07) and rs2296241 (AA vs. GG, OR = 1.27, 95% CI 0.76--1.55, *p* = 0.09), respectively. For *VDR* polymorphisms, *bovine submaxillary mucin* (*Bsm1*) (rs1544410) and *Taq1* (rs731236), were associated with reduction in risk of NSCLC, (*AA* vs. *GG*, OR = 0.71 95% CI 0.68--0.96; *p* = 0.032; CC vs. TT, OR = 0.84, 95% CI 0.56--0.98, *p* = 0.037, respectively). For *GC* gene polymorphisms, we also found that there was a statistically significant reduction of NSCLC risk in rs7041 (TT vs. GG, OR = 0.61, 95% CI 0.41--0.93; *p* \< 0.001). Moreover, we did not observe any significant impact of *CYP27B1* polymorphisms on risk of NSCLC. After we adjusted for multiple comparisons, none of the SNP-NSCLC risk *p* values were \<0.002 and the threshold was determined using the Bonferroni correction.

2.3. Plasma 25(OH)D Concentrations with Different Genotypes {#sec2dot3-ijms-17-01597}
-----------------------------------------------------------

The overall plasma 25(OH)D concentrations were slightly higher in the controls than in the other cases, but no statistically significant difference between them was observed ([Table 1](#ijms-17-01597-t001){ref-type="table"}). When correlations between SNPs and plasma 25(OH)D concentrations in cases and controls were tested, the *CYP24A1* SNP rs6068816 and *VDR* SNP rs1544410 were significantly associated with increased 25(OH)D concentration. For CC, CT, TT in rs6068816 and GG, GA, AA in rs1544410 genotypes, the means and standard deviations (SD) of plasma 25(OH)D were 16.4 ± 4.5, 20.7 ± 7.3, 25.7 ± 10.3 ng/mL (*p* = 0.007) and 16.5 ± 8.6, 20.7 ± 6.8, 25.2 ± 7.3 ng/mL (*p* = 0.009), respectively. However, the differences were not significant in the controls ([Table 4](#ijms-17-01597-t004){ref-type="table"}).

2.4. Joint Association between Vitamin D-Related Polymorphisms and Plasma 25(OH)D on NSCLC Risk {#sec2dot4-ijms-17-01597}
-----------------------------------------------------------------------------------------------

We noted an effect modification on NSCLC risk (*p* ≤ 0.01--0.05) for *CYP24A1* rs6068816, *VDR* rs10735810 and *VDR* rs1544410 polymorphisms. Homozygous for the common allele of *CYP24A1* rs6068816, *VDR* rs10735810, and *VDR* rs1544410 in patient women, with their plasma 25(OH)D of ≥20 ng/mL, had a reduced NSCLC risk compared to patient women with plasma 25(OH)D \<20 ng/mL (OR = 0.48, 95% CI 0.25--0.65; OR = 0.46, 95% CI 0.31--0.63; OR = 0.52, 95% CI 0.29--0.97, respectively, in [Table 5](#ijms-17-01597-t005){ref-type="table"}). With adjustment for multiple comparisons, none of the interaction *p* values were below the Bonferroni-determined threshold.

2.5. Plasma 25(OH)D Concentrations in Smokers and Non-Smokers with Different Genotypes {#sec2dot5-ijms-17-01597}
--------------------------------------------------------------------------------------

In the subgroup, when we compared plasma 25(OH)D concentrations with genotypes in smokers and non-smokers for both cases and control groups, the mutation genotype of *CYP24A1* rs6068816 and *VDR* rs1544410 were also significantly associated with increased 25(OH)D levels in both smokers and non-smokers in the cases group. For CC, CT, TT in rs6068816 and GG, GA, AA in rs1544410 genotypes, the means and standard deviations of plasma 25(OH)D were 14.7 ± 5.2, 16.3 ± 7.8, 18.7 ± 5.8 ng/mL (*p* = 0.02) in smokers with rs6068816, 18.4 ± 4.7, 22.4 ± 6.9, 27.2 ± 13.4 ng/mL (*p* = 0.003) in non-smokers with rs6068816, and 14.5 ± 7.8, 18.5 ± 9.6, 25.6 ± 7.0 ng/mL (*p* = 0.003) in smokers with rs1544410, 18.9 ± 10.7, 21.6 ± 4.7, 25.1 ± 7.9 (*p* = 0.01) in non-smokers with rs1544410, respectively, in the cases group. However, the differences were also not significant in smokers and non-smokers of the control group ([Table 6](#ijms-17-01597-t006){ref-type="table"}).

2.6. Interaction between Gene and Smoking {#sec2dot6-ijms-17-01597}
-----------------------------------------

When the stratified data in subgroups of subjects by cigarette smoke status were analyzed, we found that smokers and non-smokers with mutated homozygous rs2181874 in *CYP24A1* had significantly increased NSCLC risk (OR = 2.14, 95% CI 1.47--3.43; *p* = 0.031; OR = 3.57, 95% CI 2.66--4.74; *p* = 0.019, respectively). However, smokers with mutated homozygous rs6068816 in *CYP24A1* had significantly decreased NSCLC risk (OR = 0.43, 95% CI 0.27--1.02; *p* = 0.006). Smokers with mutated homozygous rs10735810 in *VDR* had significantly increased NSCLC risk (OR = 1.93, 95% CI 1.41--2.76; *p* = 0.015); smokers and non-smokers with mutated homozygous rs1544410 in *VDR* had significantly decreased NSCLC risk (OR = 0.51, 95% CI 0.34--1.17; *p* = 0.002; OR = 0.26, 95% CI 0.20--0.69; *p* = 0.001, respectively). Logistic regression analyses showed significant joint effects between smoking and *CYP24A1* rs2181874 (*p* = 0.016), *CYP24A1* rs6068816 (*p* = 0.036), *VDR* rs10735810 (*p* = 0.004), and *VDR* rs1544410 (*p* = 0.002). Detailed data are shown in [Table 7](#ijms-17-01597-t007){ref-type="table"}.

3. Discussion {#sec3-ijms-17-01597}
=============

The findings from our study did not provide evidence that higher 25(OH)D levels are related to declined NSCLC risk. These results differ from those of the Finnish study, which found that there were no associations in men or older people, while there was an opposite association between lung cancer risk and 25(OH)D levels in women or those under the age of 50 years \[[@B21-ijms-17-01597]\]. This difference may be explained by the smoking status in the current analysis. We found that the circulating 25(OH)D levels in smokers are statistically significant lower than in non-smokers, and smoking status is associated with increased risk of NSCLC, especially in concentration of plasma 25(OH)D \< 20 ng/mL. These findings stress the possibility that the increased NSCLC risk in smokers may be due to its influence on vitamin D. As we know, vitamin D has anti-inflammatory effects and promotes mechanisms of host defense, while cigarette smoke is pro-inflammatory and weakens host defense \[[@B22-ijms-17-01597]\]. Epidemiological studies suggest that non-smokers have higher levels of vitamin D than smokers \[[@B23-ijms-17-01597],[@B24-ijms-17-01597],[@B25-ijms-17-01597]\]. Cigarette smoke impairs mucociliary clearance and further damages the integrity of the respiratory epithelium \[[@B26-ijms-17-01597]\]. Cigarette smoke has also been indicated to inhibit effects of vitamin D on NF-κB signaling and produce pro-inflammatory mediators by activating epithelial cells \[[@B27-ijms-17-01597]\]. Hansdottir et al. proved that cigarette smoke interferes with vitamin D metabolism in the lungs \[[@B28-ijms-17-01597]\]. Moreover, their study showed the impact of cigarette smoke on autophagy in alveolar macrophages and on vitamin D metabolism in respiratory epithelial cells: Cigarette smoke attenuates conversion of 1,25(OH)~2~D from 25(OH)D in respiratory epithelial cells. Smokers have an increased number of autophagosomes but defective autophagosome function. Decreased local generation of active vitamin D and autophagy defects in alveolar macrophages may contribute to impaired host defense in smokers \[[@B28-ijms-17-01597]\]. Additionally, cigarette smoke may affect expression levels of the vitamin D receptor \[[@B29-ijms-17-01597]\]. Therefore, cigarette smoke decreases the production of 1,25(OH)~2~D in lung epithelial cells, which might be overcome with higher plasma 25(OH)D concentrations.

In the present study, we also explored the nominally significant relationships between genetic polymorphisms in the vitamin D metabolism and NSCLC risk. The 24-hydroxylase encoded by *CYP24A1* catalyzes the conversion of both 1,25(OH)~2~D and 25(OH)D into a series of 24- and 23-hydroxlated products targeted for excretion along well-established pathways culminating in the water-soluble biliary metabolite, a 26,23-lactone or calcitroic acid \[[@B30-ijms-17-01597]\]. CYP27B1ase catalyzes the second 1α-hydroxylation of 25(OH)D to produce 1,25(OH)~2~D in some extra-renal tissues and the kidney. Therefore, the concentrations of 25(OH)D and 1,25(OH)~2~D in blood are tightly controlled through feedback regulation of its biosynthesis and catabolism by CYP24A1ase and CYP27B1ase, respectively. A large genome-wide association study (GWAS) did not identify a significant relationship between *CYP27B1* and concentrations of circulating 25(OH)D, but variation in *CYP24A1* was significantly associated with plasma 25(OH)D concentrations \[[@B31-ijms-17-01597]\]. In the present study, an interaction between plasma 25(OH)D levels and *CYP24A1* polymorphism rs6068810 was found, while there was no relationship between rs10877012 and rs3782130 polymorphism in *CYP27B1* gene and 25(OH)D levels. Our observation is in agreement with the finding of GWAS \[[@B32-ijms-17-01597],[@B33-ijms-17-01597]\]. However, rs3782130 was located in the *CYP27B1* promoters, which are important *cis*-acting elements that regulate gene expression. Moreover, SNP in the region can influence transcription and gene function, while our findings suggested that rs3782130 variants may not result in attenuation of enzymatic activity in a Chinese population. We also found no interactions between *CYP24A1* or *CYP27B1* and polymorphism plasma 25(OH)D levels after accounting for multiple comparisons.

The CYP24A1ase plays a vital role in the vitamin D pathway, specifically regulating the level of 1,25(OH)2D \[[@B34-ijms-17-01597]\]. A number of clinical studies have indicated that *CYP24A1* is overexpressed in lung cancer patients compared with normal control tissues \[[@B35-ijms-17-01597],[@B36-ijms-17-01597],[@B37-ijms-17-01597],[@B38-ijms-17-01597]\]. Moreover, Anderson et al. demonstrated in various cancer cell lines that the anti-proliferative activity of 1,25(OH)~2~D is inversely proportional to *CYP24A1* mRNA expression \[[@B39-ijms-17-01597]\]. When testing all NSCLC cases, we identified a correlation between SNP rs6068816 in *CYP24A1* and NSCLC risk. We observed a potential 54% reduction in NSCLC risk concerning the homozygous in rs6068816 for *CYP24A1* polymorphism. The amino acid sequence of *CYP24A1* isn't altered by rs6068816 owning to a synonymous polymorphism, while it may affect intron splicing. The SNPs are located in silencers or the enhancers of splicing regions, that can influence the efficiency of mRNA splicing, and which in turn have effects on phenotype of biologic activities. Another possible reason for an association between rs6068816 in *CYP24A1* and NSCLC risk is that *CYP24A1* can evade growth control. This might be attributed to *CYP24A1* being increased in NSCLC tumors. Several studies have already examined the gain of 20q in gastro-esophageal junction \[[@B40-ijms-17-01597]\], colon \[[@B41-ijms-17-01597]\], breast \[[@B42-ijms-17-01597]\], prostate \[[@B43-ijms-17-01597]\], head and neck \[[@B44-ijms-17-01597]\] as well as lung tumors \[[@B45-ijms-17-01597],[@B46-ijms-17-01597]\]. Kong et al. reported that *CYP24A1* can reduce the 25(OH)D level and potentially increase NSCLC risk in cases with kinds of *CYP24A1* polymorphisms \[[@B47-ijms-17-01597]\]. rs6013897 was not tested in the present study due to it having been reported in the GWAS studies \[[@B31-ijms-17-01597],[@B48-ijms-17-01597],[@B49-ijms-17-01597]\], which were associated with vitamin D insufficiency.

The obvious reductions of NSCLC risk of several *VDR* polymorphisms, including rs1544410 in *Bsm1* and rs731236 in *Taq1*, were observed in our study. It is worth noting that all the *VDR* genotypes were related to declined NSCLC risk. An increased risk comparing TT vs. CC in *Taq1* in our study is consistent with the results observed in previous studies \[[@B50-ijms-17-01597],[@B51-ijms-17-01597],[@B52-ijms-17-01597]\]. On the other hand, there are a few other studies that have also found no association with increased risk \[[@B53-ijms-17-01597],[@B54-ijms-17-01597]\]. A decreased NSCLC risk with *Bsm1* in our findings is consistent with the study of Heist et al. \[[@B55-ijms-17-01597]\]. However, our study did not show other variants in *VDR* that were associated with an increased NSCLC risk.

Notably, we found that the *CYP24A1* rs6068816 and *VDR* rs1544410 were significantly associated with increased 25(OH)D concentration in cases but not in controls. Together with the relationships between NSCLC risk and variants in genes associated with *VDR* and *CYP24A1*, these results support the concept that NSCLC carcinogenesis may be influenced by the vitamin D axis, including the interaction between the different components of vitamin D, which includes circulating vitamin D, the *CYP24A1*, and the *VDR*. The reason why there is a discrepancy in these SNPs is unclear. However, these results suggest that CYP24A1 protein is rate limiting for the amount of local vitamin D in cancer tissues, and elevated expression is associated with an adverse prognosis in cancer. Moreover, by regulating the level of vitamin D, this enzyme plays a role in Ca^2+^ homeostasis. Because of its important role in vitamin D metabolism and blood Ca^2+^ homeostasis, trivial changes in vitamin D hydroxylation activity could alter disease pathogenesis and outcome. Additionally, it exerts its oncogenic activities through its expressed protein in various cancers \[[@B56-ijms-17-01597],[@B57-ijms-17-01597]\]. There is growing evidence that vitamin D may reduce the risk of developing NSCLC and that higher levels of vitamin D may be associated with better prognosis and improved outcome. However, our study did not provide the evidences that higher 25(OH)D levels are related to declined NSCLC risk, which suggests vitamin D may play a different role in disease initiation compared to disease progression, and SNPs that predict disease outcomes may be different than those that predict disease risk. There are many reports suggesting that vitamin D can reduce tumor growth of lung cancer in vitro \[[@B58-ijms-17-01597]\] and in vivo \[[@B59-ijms-17-01597]\].

Meanwhile, we found that smokers with homozygous for the common allele of *CYP24A1* rs6068816, *VDR* rs10735810, and *VDR* rs1544410 who had plasma 25(OH)D of ≥20 ng/mL had a significantly reduced NSCLC risk compared to women with plasma 25(OH)D \<20 ng/mL. However, results showed that smokers with mutated homozygous *CYP24A1* rs2181874 and *VDR* rs10735810 had significantly increased NSCLC risk. The joint effects between smoking and *CYP24A1* rs2181874, *CYP24A1* rs6068816, *VDR* rs10735810, and *VDR* rs1544410 suggest *CYP24A1* rs6068816 and *VDR* rs1544410 mutations may reduce NSCLC susceptibility, whereas *CYP24A1* rs2181874 and *VDR* rs10735810 mutations may increase NSCLC susceptibility, especially in the smoking population. However, the possibility of false-positive results in the reported two joint-association analyses should be considered. Firstly, we did not extrapolate other populations in other areas excluding the Yunnan district, so the results have some limitation. Second, the smoker sample size in our study is comparatively small, which may not have enough statistical power to explore the true association, especially for haplotype analysis. Thirdly, there is the possibility of passive smoking or second-hand smoking in the cases' family. Notably, Asian never-smoking females have an elevated incidence of lung cancer and lung cancer-related death rates compared with the European population \[[@B60-ijms-17-01597]\]. It has been speculated that the high rate of lung cancer in Asian never-smokers is due to environmental factors such as second-hand smoke or cooking style \[[@B61-ijms-17-01597],[@B62-ijms-17-01597]\]. Exposure to these carcinogens would lead to increased oxidative damage and an increase in the G\>T transversion mutation rate \[[@B63-ijms-17-01597]\]. We did not survey the degree of second-hand smoke exposure in our never-smoking patients. This raises the possibility that secondary tobacco smoke could be a confounding factor in these patients. Additionally, we did not observe a smoker-like mutation signature in any of our never-smoker patients, suggesting that this confounder might not be significant for our conclusions. One would expect long-term quitters to have a mutational pattern similar to that of never-smokers, and short-term quitters to resemble that of current smokers. It is known that 5 to 9 years of smoking cessation can lower the risk of lung cancer \[[@B64-ijms-17-01597]\]. Therefore, the never-smoker-like signature in these patients cannot be accounted for by having quit smoking a long time ago. This highlights the importance of checking the molecular signature of patients with lung cancer irrespective of smoking status.

We explored two rather common SNPs, rs4588 and rs7041 in *GC*. Previous lung cancer studies have reported various results \[[@B65-ijms-17-01597],[@B66-ijms-17-01597]\]. In the current study, it is shown that slight increases in NSCLC risk with rs7041 polymorphisms for rs7041 was a common nonsynonymous SNP in the *GC* gene. Previous studies have investigated rs7041 in relation to prostate cancer \[[@B67-ijms-17-01597],[@B68-ijms-17-01597]\], breast cancer \[[@B69-ijms-17-01597]\], basal cell carcinomas \[[@B70-ijms-17-01597]\] and colon \[[@B71-ijms-17-01597]\]. Our study indicates that rs7041 may be related to reduced NSCLC risk, which was similar to one recent study \[[@B47-ijms-17-01597]\].

Our findings did not show that the *GC* polymorphism is associated with 25(OH)D levels. Overall, our results support the hypothesis that NSCLC carcinogenesis might be affected by the vitamin D levels and the interaction between the genetic variation and cigarette smoke. Further studies with larger sample size on interactions with calcium, plasma 25(OH)D levels, and vitamin D intake should be evaluated in terms of cancer occurrence.

4. Materials and Methods {#sec4-ijms-17-01597}
========================

4.1. Case and Control Selection {#sec4dot1-ijms-17-01597}
-------------------------------

Eligible patients diagnosed with histologically confirmed primary NSCLC (*n* = 426) were enrolled in our study. We used the seventh edition of the TNM Classification of Malignant Tumors published in 2009 \[[@B72-ijms-17-01597]\]. All cases were randomly selected for the study at the Third Affiliated Hospital of Kunming Medical College (TAHKMC) during July 2013 to December 2014. Clinical information collected in our study includes disease stage, tumor size, histological type, and lymph node metastasis. There were 334 cases of adenocarcinoma, 59 of squamous cell carcinoma (SCC), 25 of adenosquamous carcinoma and 8 cases of carcinoid tumor. As regards to the degree of differentiation, 50 of the cases were well differentiated, 234 were moderately differentiated and 142 were poorly differentiated. A total of 175 cases presented lymph node metastasis. In terms of postoperative pathological classification, 98 patients had stage IA, 69 had stage IB, 51 had stage IIA, 49 had stage IIB, 134 had stage IIIA, 17 had stage IIIB and 8 had stage IV disease.

The control subjects (*n* = 445) were recruited from the health check-up in the same hospital during the same period as the cases were recruited. Eventually, the controls were individually frequency-matched 1:1 with the cases for age (±6.2 years), race, gender, and date of blood collection (±1 month). All subjects of cases and controls agreed to participate and gave written, informed consent, and completed an in-person interview executed by a trained assistant of the study using a structured questionnaire. The questionnaire elicits information on sociodemographic characteristics and a number of potential risks including cigarette use, alcohol use, regular exercise, drinking habits, as well as eating habits including intake of milk, egg, any kind of meat (pork, beef, game, chick, duck, fatty fish, fish liver oil), fresh fruit, green vegetables, tea, coffee, pickled products. Medical history, history of pulmonary disease, family history of lung cancer as well as other lifestyle behaviors were also considered. Exclusion criteria included symptomatic brain metastases, spinal cord compression, uncontrolled massive pleural effusion, and other chronic diseases including history of pulmonary disease, and preoperative radiotherapy or chemotherapy \[[@B53-ijms-17-01597],[@B73-ijms-17-01597]\]. Subjects taking calcium and vitamin D supplements during the previous 6 months were also excluded from the study. Smoking status was categorized as never smoking, current smoking and past smoking based on two questions: "Have you smoked more than 100 cigarettes in your life?" and "I used to smoke until the age of ...". Current smoking was defined as smoking either daily or less than daily (occasionally) up to his/her current age and having smoked more than 100 cigarettes in a lifetime. Past smoking was defined as having smoked more than 100 cigarettes and having stopped smoking for at least one year. Quit ratio was calculated as the ratio of the number of past smokers over the number of ever-smokers, i.e., total of current and past smokers \[[@B74-ijms-17-01597]\].

4.2. Vitamin D Assay {#sec4dot2-ijms-17-01597}
--------------------

Non-fasting baseline blood specimens were collected at the clinical centers. Quantification of plasma 25(OH)D was tested by radioimmunoassay (RIA) method (DiaSorin, Stillwater, MN, USA) \[[@B75-ijms-17-01597]\]. Cases and controls were inspected continuously within batches. Details of the plasma 25(OH)D measurements have been described previously \[[@B12-ijms-17-01597]\]. Assays were run in two batches; Quality controls (QC) were utilized to assess inter-assay accuracy and precision. During each run, QC samples (*n* = 5) were run together with the study samples. QC samples (*n* = 2; 17.3 and 50.4 ng/mL), pooled plasma samples (*n* = 1; 23.6 ng/mL) and commercially available external QC samples (*n* = 2; 63.9 and 107.9 ng/mL) provided by DiaSorin. The overall coefficients of variation (CVs) from blinded replicate QC samples in each batch were 9.6% and 5.8%. Laboratory staffs have been blinded to QC and control-case status.

4.3. SNP Selection and Genotyping Analysis {#sec4dot3-ijms-17-01597}
------------------------------------------

We used the following criteria to select a set of multi-population tag single-nucleotide polymorphisms (SNPs): (1) potentially functional, i.e. located in the 5′ flanking regions; the base pair change needs to be in predicted regulatory sequences in a promoter; 5′ untranslated (UTR) or 3′ untranslated (UTR) region could affect splicing or code regions with amino acid substitution or frequently studied variants from previous reports \[[@B76-ijms-17-01597]\]; (2) minor allele frequencies of at least 5% and an r^2^ ≥ 80% were selected; and (3) related to plasma vitamin D levels in genome-wide association studies \[[@B77-ijms-17-01597],[@B78-ijms-17-01597]\]. The 15 SNPs for genotyping were selected. They included five SNPs in *VDR*: *Bsm1* (rs1544410), *Taq1* (rs731236), *Apa1* (rs7975232), *Fok1* (rs10735810), *Cdx2* (rs11568820); six SNPs in 24-hydroxylase (*CYP24A1*): rs6068816, rs2244719, rs4809960, rs2762939, rs2181874, and rs2296241; two SNPs in the vitamin D-binding protein (*GC*): rs7041 and rs4588; and two SNPs in 1α-hydroxylase (*CYP27B1*): rs10877012 and rs3782130. Assays at all sites included at least two negative controls and replicate quality control samples (5% samples) per genotyping plates. The concordance rate between duplicate DNA samples ranged from 92% to 100% and completion rates ranged from 98% to 100%. The genotype frequencies among controls did not differ from the expected Hardy-Weinberg equilibrium proportions (*p* \> 0.05).

Genomic DNA was extracted from fresh or frozen whole blood using a commercially available FlexiGen DNA isolation kit (Qiagen, Valencia, CA, USA) \[[@B79-ijms-17-01597]\]. The PCR-RFLP method was used for genotyping each polymorphism. The sequences of the forward and reverse primers, the PCR conditions and characteristics of the SNPs used are summarized in [Supplementary Materials Table S1 and Figure S2](#app1-ijms-17-01597){ref-type="app"}. Laboratory staff were blinded to the case-control status of the samples.

4.4. Statistical Analysis {#sec4dot4-ijms-17-01597}
-------------------------

Chi-square test was used to compare the frequency distributions between cases and controls of demographic variable, environmental factors and gene polymorphisms. For continuous variables, differences were compared by analysis of variance (ANOVA) or Student *t*-tests. The deviation from Hardy-Weinberg equilibrium (HWE) in controls and cases for each polymorphism were tested in our study. The unconditional logistic regression model was used to evaluate the connections between SNPs and NSCLC risk. In logistic regression analysis, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated with adjustment for confounding factors. Subgroup analyses were also performed for each polymorphism by smoking status. The log-transformed plasma 25(OH)D concentrations were used to normalize the distribution of 25(OH)D. The multiple testing was performed by the Bonferroni method. All reported *p* values are two-sided. Results were considered statistically significant when the *p* value was smaller than 0.05. To assess the genotype score, we selected the SNP with the strongest evidence for association at each locus. We determined the inheritance model (dominant, recessive, or additive) for each individual SNP by analyzing the β-coefficients (log \[odds ratio (OR)\]) of the genotypes as categorical variables in logistic regression models adjusted for age, gender, and family history of NSCLC, and BMI ([Table 3](#ijms-17-01597-t003){ref-type="table"}). In the dominant model, heterozygous genotypes were recoded as homozygous risk genotypes; in the recessive model, heterozygous genotypes were recoded as homozygous non-risk, whereas we coded genotypes as 0 for the non-risk homozygous genotype, 1 for the heterozygous genotype, and 2 for the homozygous risk genotype. In the additive model, the risk scores remained unchanged \[[@B80-ijms-17-01597]\]. All statistical analyses were conducted using the SPSS statistical package, version 12.0 (IBM SPSS Inc., Chicago, IL, USA) and Stata/SE 11.0 (StataCorp, College Station, TX, USA).

5. Conclusions {#sec5-ijms-17-01597}
==============

In conclusion, we did not find that higher, prediagnostic levels of either vitamin D metabolite were associated with lower risk of NSCLC in Han Chinese. However, cigarette smoking may lead to the deficiency of vitamin D. Because vitamin D plays an important role in calcium absorption and bone health, cigarette smokers should increase their vitamin D intake. Furthermore, the specific vitamin D-related SNPs were associated with NSCLC risk, which supports the biologic explanation of a connection between the vitamin D pathway and NSCLC risk in a portion of the population with underlying genetic susceptibility. The relationship between NSCLC and circulating 25(OH)D should be explored in larger populations and different races in China. Prospective studies of long-term sun exposure could also be valuable in clarifying the role of vitamin D in NSCLC risk, although there are certainly substantial difficulties in estimating such exposures. Lastly, further investigations are necessary to replicate this finding and explore biological underpinnings of the plausibility of a gene-environment interaction, such as sun exposure, as it may yield additional insight into the association of vitamin D and NSCLC risk.
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###### 

Descriptive characteristics of non-small cell lung cancer (NSCLC).

  Characteristics                         Cases (*n* = 426)   Controls (*n* = 445)   *p*
  --------------------------------------- ------------------- ---------------------- ---------
  Age, years                                                                         0.283
  Mean ± SD                               57.4 ± 5.8          59.6 ± 4.7             
  Gender (%)                                                                         0.447
  Male                                    242 (56.8)          269 (60.4)             
  Female                                  184 (43.2)          176 (39.6)             
  Races (Han, %)                          426 (100)           445 (100)              1
  Married (%)                                                                        0.057
  Yes                                     374 (87.8)          401 (90.1)             
  No                                      52 (12.2)           44 (9.9)               
  BMI, kg/m^2^ (% ^a^)                                                               0.2
  \<25.0                                  94 (22.4)           65 (14.8)              
  ≥25.0                                   325 (77.6)          375 (85.2)             
  Missing ^b^                             7                   5                      
  Family history of lung cancer (% ^a^)                                              \<0.001
  Yes                                     74 (17.8)           41 (9.5)               
  No                                      341 (82.2)          390 (90.5)             
  Missing ^b^                             11                  14                     
  Education (% ^a^)                                                                  
  Less than high school                   82 (19.5)           65 (14.8)              
  High school graduate                    339 (80.5)          373 (85.2)             
  Missing ^b^                             5                   7                      
  Leisure physical activity (% ^a^)                                                  0.252
  \<3 times/week                          89 (21.2)           111 (25.6)             
  ≥3 times/week                           330 (78.8)          322 (74.4)             
  Missing ^b^                             7                   12                     
  Dietary vitamin D intake (μg/day)       5.7 ± 2.4           5.4 ± 3.1              0.759
  Smoking history (% ^a^)                                                            
  Yes                                     297 (70.0)          214 (48.5)             0.001
  No                                      127 (30.0)          227 (51.5)             
  Missing ^b^                             2                   4                      
  Alcohol use (% ^a^)                                                                0.132
  Yes                                     261 (61.6)          275 (63.2)             
  No                                      163 (38.4)          160 (36.8)             
  Missing ^b^                             2                   10                     
  Plasma 25(OH)D (ng/mL)                                                             0.251
  Mean ± SD                               21.0 ± 6.3          22.5 ± 7.3             

^a^ Percent of non-missing total; ^b^ Missing total not included in the percent distribution calculation; Standard Deviation (SD); body mass index (BMI); 25-hydroxy vitamin D \[25(OH)D\].
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###### 

Odds ratios (ORs) and 95% confidence intervals (CIs) for associations between the smoking and NSCLC risk was stratified by 25(OH)D.

               Concentration of Plasma 25(OH)D ^a,b^                                
  ------------ --------------------------------------- ------------------- -------- -------------------
  Non-smoker   85/149                                  1.00 (ref)          42/78    1.00 (ref)
  Smoker       174/117                                 2.74 (1.97--3.01)   123/97   2.48 (2.05--2.97)
  *p*                                                  \<0.001                      \<0.001

^a^ Missing value = 2 in case groups, Missing value = 4 in control groups; ^b^ Vitamin D deficiency was defined as 25(OH)D \< 20 ng/mL; vitamin D sufficiency was defined as 25(OH)D ≥ 20ng/mL; ^c^ Covariates used for adjustment included age, gender, and family history NSCLC, and BMI.
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###### 

OR and 95% CIs for associations between vitamin D-related genotypes and NSCLC risk.

  Gene (Reference SNP number, rs)   Genotype   Cases (*n* = 426)   Controls (*n* = 445)   OR ^a^ (95% CI)     *p*
  --------------------------------- ---------- ------------------- ---------------------- ------------------- ---------
  *VDR* (rs10735810)                CC         166 (39.0%)         160 (36.0%)            1.00 (ref)          0.47
                                    CT         192 (45.1%)         204 (45.8%)            0.97 (0.73--1.41)   
                                    TT         68 (15.9%)          81 (18.2%)             1.15 (0.84--1.37)   
                                    TT + CT    260 (61.0%)         285 (64.0%)            1.09 (0.81--1.44)   
  *VDR* (rs11568820)                TT         63 (14.8%)          52 (11.7%)             1.00 (ref)          0.25
                                    TC         324 (76.1%)         360 (80.9%)            1.22 (0.85--1.47)   
                                    CC         39 (9.1%)           33 (7.4%)              0.96 (0.79--1.29)   
                                    CC + TC    363 (85.2%)         393 (88.3%)            1.12 (0.87--1.54)   
  *VDR* (rs1544410)                 GG         403 (94.6%)         373 (83.8%)            1.00 (ref)          0.032
                                    GA         17 (4.0%)           49 (11.0%)             0.79 (0.64--1.13)   
                                    AA         6 (1.4%)            23 (5.2%)              0.78 (0.68--0.96)   
                                    AA + GA    23 (5.4%)           72 (16.2%)             0.78 (0.65--1.07)   
  *VDR* (rs7975232)                 CC         140 (32.9%)         142 (31.9%)            1.00 (ref)          0.76
                                    CA         191 (44.8%)         214 (48.1%)            1.11 (0.84--1.47)   
                                    AA         95 (22.3%)          89 (20.0%)             0.99 (0.63--1.35)   
                                    AA + CA    286 (67.1%)         303 (68.1)             1.02 (0.75--1.39)   
  *VDR* (rs731236)                  TT         409 (96.0%)         416 (93.5%)            1.00 (ref)          0.037
                                    TC         14 (3.3%)           27 (6.1%)              0.77 (0.59--0.99)   
                                    CC         3 (0.7%)            2 (0.4%)               0.84 (0.57--0.95)   
                                    CC + TC    17 (4.0%)           29 (6.5%)              0.79 (0.60--0.91)   
  *CYP24A1* (rs6068816)             CC         170 (39.9%)         76 (17.1%)             1.00 (ref)          \<0.001
                                    CT         222 (52.1%)         307 (69.0%)            0.85 (0.67--1.32)   
                                    TT         34 (8.0%)           62 (13.9%)             0.31 (0.21--0.47)   
                                    TT + CT    256 (60.1%)         369 (82.9%)            0.72 (0.58--1.02)   
  *CYP24A1* (rs2244719)             TT         312 (73.2%)         320 (71.9%)            1.00 (ref)          0.65
                                    TC         89 (20.9%)          87 (19.6%)             1.10 (0.92--1.35)   
                                    CC         25 (5.9%)           38 (8.5%)              0.95 (0.77--1.16)   
                                    CC + TC    114 (26.8%)         125 (28.1%)            1.04 (0.88--1.23)   
  *CYP24A1* (rs4809960)             TT         349 (81.9%)         360 (80.9%)            1.00 (ref)          0.14
                                    TC         62 (14.6%)          75 (16.9%)             0.85 (0.74--0.99)   
                                    CC         15 (3.5%)           10 (2.2%)              1.09 (0.78--1.52)   
                                    CC + TC    77 (18.1%)          85 (19.1%)             0.97 (0.75--1.21)   
  *CYP24A1* (rs2762939)             GG         160 (37.5%)         156 (35.1%)            1.00 (ref)          0.50
                                    GC         192 (45.1%)         220 (49.4%)            1.09 (0.85--1.32)   
                                    CC         74 (17.4%)          69 (15.5%)             1.06 (0.79--1.33)   
                                    CC + GC    266 (62.5%)         289 (64.9%)            1.08 (0.73--1.25)   
  *CYP24A1* (rs2181874)             GG         303 (71.1%)         340 (76.4%)            1.00 (ref)          0.07
                                    GA         84 (19.7%)          76 (17.1%)             1.17 (0.92--1.37)   
                                    AA         39 (9.2%)           29 (6.5%)              1.40 (0.85--1.92)   
                                    AA + GA    123 (28.9%)         105 (23.6%)            1.33 (0.89--1.65)   
  *CYP24A1* (rs2296241)             GG         119 (27.9%)         114 (25.6%)            1.00 (ref)          0.09
                                    GA         230 (54.0%)         227 (51.0%)            1.30 (0.88--1.63)   
                                    AA         77 (18.1%)          104 (23.4%)            1.27 (0.76--1.55)   
                                    AA + GA    307 (72.1%)         331 (74.4%)            1.29 (0.92--1.72)   
  *CYP27B1* (rs10877012)            GG         165 (38.7%)         160 (35.9%)            1.00 (ref)          0.37
                                    GT         209 (49.1%)         209 (47.0%)            1.10 (0.88--1.35)   
                                    TT         52 (12.2%)          76 (17.1%)             0.95 (0.76--1.21)   
                                    TT + GT    261 (61.3%)         285 (64.1%)            1.01 (0.75--1.32)   
  *CYP27B1* (rs3782130)             CC         194 (45.5%)         187 (42.1%)            1.00 (ref)          0.15
                                    CG         149 (35.0%)         163 (36.6%)            0.82 (0.76--1.45)   
                                    GG         83 (19.5%)          95 (21.3%)             1.03 (0.89--1.34)   
                                    GG + CG    232 (54.5%)         258 (57.9%)            0.94 (0.78--1.38)   
  *GC* (rs7041)                     TT         175 (41.1%)         173 (38.8%)            1.00 (ref)          \<0.001
                                    TG         230 (54.0%)         225 (50.6%)            0.79 (0.44--0.97)   
                                    GG         21 (4.9%)           47 (10.6%)             0.61 (0.41--0.93)   
                                    GG + TG    251 (58.9%)         272 (61.2%)            0.69 (0.38--1.15)   
  *GC* (rs4588)                     CC         230 (54.0%)         235 (52.8%)            1.00 (ref)          0.58
                                    CA         170 (39.9%)         173 (38.9%)            1.14 (0.91--1.45)   
                                    AA         26 (6.1%)           37 (8.3%)              0.93 (0.71--1.43)   
                                    AA + CA    196 (46.0%)         210 (47.2%)            1.11 (0.93--1.28)   

^a^ Covariates used for adjustment included age, gender, and family history of NSCLC and BMI.
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###### 

Comparison of plasma 25(OH)D concentrations (ng/mL) by polymorphisms in the vitamin D-related gene.

  Gene (rs) Case/Control   Homozygous Common Allele (Mean ± SD)   Heterozygous (Mean ± SD)   Homozygous Minor Allele (Mean ± SD)   Heterozygous + Homozygous Minor Allele (Mean ± SD)   *p* ^a^   *p* ^b^
  ------------------------ -------------------------------------- -------------------------- ------------------------------------- ---------------------------------------------------- --------- ---------
  *VDR* (rs10735810)       CC                                     CT                         TT                                    TT + CT                                                        
  Cases                    21.5 ± 6.7                             22.6 ± 7.7                 20.6 ± 8.5                            22.0 ± 7.1                                           0.56      0.67
  Controls                 26.1 ± 5.4                             25.3 ± 6.7                 24.5 ± 8.2                            24.9 ± 7.8                                           0.55      0.47
  *VDR* (rs11568820)       TT                                     TC                         CC                                    CC + TC                                                        
  Cases                    27.0 ± 6.4                             24.9 ± 8.4                 27.4 ± 7.4                            25.9 ± 8.9                                           0.70      0.45
  Controls                 25.7 ± 9.2                             27.4 ± 8.0                 27.1 ± 10.3                           27.3 ± 7.4                                           0.56      0.87
  *VDR* (rs1544410)        GG                                     GA                         AA                                    AA + GA                                                        
  Cases                    16.5 ± 8.6                             20.7 ± 6.8                 25.2 ± 7.3                            24.6 ± 7.4                                           0.009     0.008
  Controls                 21.7 ± 4.6                             23.0 ± 7.1                 23.4 ± 7.0                            23.1 ± 6.9                                           0.23      0.39
  *VDR* (rs7975232)        CC                                     CA                         AA                                    AA + CA                                                        
  Cases                    26.7 ± 6.7                             25.9 ± 5.1                 28.1 ± 7.7                            26.9 ± 8.0                                           0.89      0.87
  Controls                 28.9 ± 5.7                             25.8 ± 7.9                 27.9 ± 7.3                            27.1 ± 8.8                                           0.65      0.31
  *VDR* (rs731236)         TT                                     TC                         CC                                    CC + TC                                                        
  Cases                    24.5 ± 6.8                             24.5 ± 6.9                 23.4 ± 6.1                            24.5 ± 5.4                                           0.70      0.87
  Controls                 27.7 ± 9.8                             26.8 ± 5.1                 28.6 ± 6.4                            27.6 ± 7.5                                           0.80      0.65
  *CYP24A1* (rs6068816)    CC                                     CT                         TT                                    TT + CT                                                        
  Cases                    16.4 ± 4.5                             20.7 ± 7.3                 25.7 ± 10.3                           23.8 ± 7.7                                           0.007     0.01
  Controls                 17.9 ± 5.2                             18.9 ± 7.8                 18.4 ± 7.1                            18.5 ± 7.2                                           0.20      0.27
  *CYP24A1* (rs2244719)    TT                                     TC                         CC                                    CC + TC                                                        
  Cases                    28.6 ± 8.2                             27.6 ± 7.8                 29.0 ± 6.9                            28.3 ± 6.2                                           0.80      0.85
  Controls                 26.8 ± 7.2                             27.4 ± 6.5                 25.5 ± 6.3                            27.2 ± 6.3                                           0.51      0.44
  *CYP24A1* (rs4809960)    TT                                     TC                         CC                                    CC + TC                                                        
  Cases                    24.6 ± 6.1                             26.8 ± 8.2                 25.7 ± 7.7                            27.6 ± 7.4                                           0.76      0.60
  Controls                 25.9 ± 6.5                             26.5 ± 7.6                 27.7 ± 8.6                            27.0 ± 8.0                                           0.62      0.56
  *CYP24A1* (rs2762939)    GG                                     GC                         CC                                    CC + GC                                                        
  Cases                    25.9 ± 4.8                             27.9 ± 7.1                 27.1 ± 8.9                            27.8 ± 7.0                                           0.61      0.70
  Controls                 31.4 ± 10.1                            29.6 ± 8.9                 29.7 ± 11.6                           29.0 ± 10.5                                          0.90      0.93
  *CYP24A1* (rs2181874)    GG                                     GA                         AA                                    AA + GA                                                        
  Cases                    26.2 ± 6.1                             24.4 ± 5.7                 24.4 ± 7.8                            24.5 ± 7.6                                           0.29      0.15
  Controls                 28.1 ± 5.7                             26.7 ± 8.9                 24.9 ± 5.7                            25.4 ± 8.1                                           0.13      0.09
  *CYP24A1* (rs2296241)    GG                                     GA                         AA                                    AA + GA                                                        
  Cases                    24.6 ± 9.6                             21.9 ± 9.5                 20.5 ± 8.7                            21.5 ± 8.5                                           0.13      0.21
  Controls                 25.7 ± 11.2                            23.4 ± 10.1                24.0 ± 10.4                           24.9 ± 9.5                                           0.36      0.61
  *CYP27B1* (rs10877012)   GG                                     GT                         TT                                    TT + GT                                                        
  Cases                    28.1 ± 7.7                             28.0 ± 8.3                 29.4 ± 10.1                           28.6 ± 9.8                                           0.80      0.71
  Controls                 27.1 ± 8.3                             27.9 ± 4.9                 29.9 ± 8.7                            29.1 ± 5.6                                           0.33      0.34
  *CYP27B1* (rs3782130)    CC                                     CG                         GG                                    GG + CG                                                        
  Cases                    27.0 ± 6.7                             27.8 ± 8.9                 25.7 ± 6.1                            26.4 ± 7.4                                           0.81      0.77
  Controls                 26.5 ± 8.1                             28.5 ± 14.3                28.2 ± 8.6                            28.6 ± 10.7                                          0.25      0.10
  *GC* (rs7041)            TT                                     TG                         GG                                    GG + TG                                                        
  Cases                    24.7 ± 8.0                             25.6 ± 6.9                 26.1 ± 7.3                            26.0 ± 6.3                                           0.37      0.43
  Controls                 28.0 ± 10.2                            27.8 ± 7.1                 29.5 ± 7.3                            29.1 ± 8.4                                           0.87      0.61
  *GC* (rs4588)            CC                                     CA                         AA                                    AA + CA                                                        
  Cases                    24.7 ± 7.1                             26.7 ± 7.9                 27.1 ± 6.9                            26.9 ± 7.1                                           0.73      0.74
  Controls                 27.2 ± 7.1                             27.0 ± 7.5                 29.1 ± 10.8                           28.0 ± 6.5                                           0.19      0.41

^a^ Comparing across all three genotypes; ^b^ Comparing homozygous major genotype to the combination of heterozygous and homozygous minor genotypes.
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###### 

ORs and 95% CIs for the joint association between vitamin D-related polymorphisms and plasma 25(OH)D on NSCLC risk.

                           Homozygous Common Allele   Heterozygous and Homozygous Minor Allele                                                     
  ------------------------ -------------------------- ------------------------------------------ ------------------- --------- ------------------- -------
  *VDR* (rs10735810)       \<20 ng/mL                 47/38                                      1.00 (ref)          78/56     1.00 (ref)          0.015
                           ≥20 ng/mL                  119/122                                    0.47 (0.24--1.43)   182/229   0.46 (0.31--0.63)   
  *VDR* (rs11568820)       \<20 ng/mL                 16/11                                      1.00 (ref)          109/81    1.00(ref)           0.263
                           ≥20 ng/mL                  47/41                                      0.66 (0.34--1.52)   254/312   0.68 (0.47--0.95)   
  *VDR* (rs1544410)        \<20 ng/mL                 123/81                                     1.00 (ref)          6/15      1.00 (ref)          0.021
                           ≥20 ng/mL                  280/292                                    0.73 (0.44--1.07)   17/57     0.52 (0.29--0.97)   
  *VDR* (rs7975232)        \<20 ng/mL                 42/29                                      1.00 (ref)          84/64     1.00 (ref)          0.631
                           ≥20 ng/mL                  98/113                                     0.69 (0.41--1.21)   202/239   0.74 (0.59--1.32)   
  *VDR* (rs731236)         \<20 ng/mL                 124/83                                     1.00 (ref)          5/6       1.00 (ref)          0.841
                           ≥20 ng/mL                  285/333                                    0.55 (0.27--0.66)   12/23     0.60 (0.39--0.88)   
  *CYP24A1* (rs6068816)    \<20 ng/mL                 49/16                                      1.00 (ref)          82/79     1.00 (ref)          0.002
                           ≥20 ng/mL                  121/60                                     0.41(0.28--0.61)    174/290   0.48(0.25--0.65)    
  *CYP24A1* (rs2244719)    \<20 ng/mL                 87/66                                      1.00 (ref)          35/26     1.00 (ref)          0.731
                           ≥20 ng/mL                  225/254                                    0.65 (0.42--0.91)   79/99     0.78 (0.49--0.99)   
  *CYP24A1* (rs4809960)    \<20ng/mL                  100/71                                     1.00 (ref)          23/18     1.00 (ref)          0.724
                           ≥20 ng/mL                  249/289                                    0.58 (0.31--1.05)   54/67     0.67 (0.45--0.88)   
  *CYP24A1* (rs2762939)    \<20 ng/mL                 47/33                                      1.00 (ref)          78/61     1.00 (ref)          0.691
                           ≥20 ng/mL                  113/123                                    0.67 (0.49--0.98)   188/228   0.53 (0.31--0.87)   
  *CYP24A1* (rs2181874)    \<20 ng/mL                 98/77                                      1.00 (ref)          46/21     1.00 (ref)          0.113
                           ≥20 ng/mL                  205/263                                    0.47 (0.28--0.90)   77/84     0.72 (0.58--0.93)   
  *CYP24A1* (rs2296241)    \<20 ng/mL                 33/23                                      1.00 (ref)          95/73     1.00 (ref)          0.832
                           ≥20 ng/mL                  86/91                                      0.79 (0.58--1.09)   212/258   0.61 (0.40--0.97)   
  *CYP27B1* (rs10877012)   \<20 ng/mL                 48/32                                      1.00 (ref)          78/64     1.00 (ref)          0.875
                           ≥20 ng/mL                  117/128                                    0.71 (0.53--0.98)   183/221   0.74 (0.49--1.14)   
  *CYP27B1* (rs3782130)    \<20 ng/mL                 53/28                                      1.00 (ref)          70/62     1.00 (ref)          0.962
                           ≥20 ng/mL                  141/159                                    0.80 (0.69--1.24)   162/196   0.73 (0.53--1.00)   
  *GC* (rs7041)            \<20 ng/mL                 43/36                                      1.00 (ref)          73/59     1.00 (ref)          0.182
                           ≥20 ng/mL                  132/137                                    0.95 (0.81--1.53)   178/213   0.57 (0.41--0.82)   
  *GC* (rs4588)            \<20 ng/mL                 61/43                                      1.00 (ref)          64/51     1.00 (ref)          0.804
                           ≥20 ng/mL                  169/192                                    0.52 (0.31--0.90)   132/159   0.71 (0.39--0.86)   

^a^ Vitamin D deficiency was defined as 25(OH)D \<20 ng/mL; vitamin D sufficiency was defined as 25(OH)D ≥20 ng/mL; ^b^ Interaction is between plasma 25(OH)D and the homozygous common allele and heterozygous or homozygous minor allele, with \<20 ng/mL as the reference.
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###### 

Comparison of plasma 25(OH)D concentrations (ng/mL) in smokers and non-smokers with different polymorphisms.

  Gene (rs) Case/Control Smoking Status   Homozygous Common Allele (Mean ± SD)   Heterozygous (Mean ± SD)   Homozygous Minor Allele (Mean ± SD)   Heterozygous + Homozygous Minor Allele (Mean ± SD)   *p* ^a^   *p* ^b^
  --------------------------------------- -------------------------------------- -------------------------- ------------------------------------- ---------------------------------------------------- --------- ---------
  *VDR* (rs10735810)                      CC                                     CT                         TT                                    TT + CT                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  19.4 ± 7.8                             16.9 ± 6.8                 17.8 ± 5.9                            17.5 ± 6.0                                           0.67      0.32
  Non-smoker                              24.8 ± 4.5                             26.4 ± 10.6                21.8 ± 7.2                            23.6 ± 8.4                                           0.45      0.87
  Controls                                                                                                                                                                                                       
  Smoker                                  26.8 ± 3.5                             24.7 ± 5.7                 23.6 ± 5.4                            24.1 ± 5.4                                           0.78      0.65
  Non-smoker                              25.8 ± 6.4                             28.6 ± 9.3                 24.6 ± 7.1                            26.8 ± 8.2                                           0.41      0.44
  *VDR* (rs11568820)                      TT                                     TC                         CC                                    CC + TC                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  26.7 ± 7.8                             25.8 ± 10.5                27.8 ± 10.2                           26.6 ± 9.5                                           0.88      0.62
  Non-smoker                              27.8 ± 6.1                             24.7 ± 7.9                 26.3 ± 8.6                            25.4 ± 7.2                                           0.75      0.37
  Controls                                                                                                                                                                                                       
  Smoker                                  24.7 ± 6.7                             25.8 ± 7.8                 27.4 ± 8.8                            26.4 ± 5.5                                           0.53      0.78
  Non-smoker                              26.7 ± 7.8                             28.5 ± 9.2                 26.6 ± 9.1                            27.6 ± 7.9                                           0.84      0.93
  *VDR* (rs1544410)                       GG                                     GA                         AA                                    AA + GA                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  14.5 ± 7.8                             18.5 ± 9.6                 25.6 ± 7.0                            24.1 ± 8.8                                           0.005     0.003
  Non-smoker                              18.9 ± 10.7                            21.6 ± 4.7                 25.1 ± 7.9                            24.7 ± 5.6                                           0.01      0.01
  Controls                                                                                                                                                                                                       
  Smoker                                  19.6 ± 12.5                            22.4 ± 6.7                 24.9 ± 7.8                            23.8 ± 8.9                                           0.67      0.76
  Non-smoker                              22.3 ± 6.2                             24.9 ± 7.5                 25.4 ± 5.6                            25.0 ± 7.5                                           0.08      0.12
  *VDR* (rs7975232)                       CC                                     CA                         AA                                    AA + CA                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  26.5 ± 12.2                            25.7 ± 10.7                27.0 ± 5.6                            26.3 ± 6.2                                           0.86      0.90
  Non-smoker                              28.9 ± 14.5                            26.6 ± 6.2                 28.4 ± 7.2                            27.4 ± 7.3                                           0.91      0.76
  Controls                                                                                                                                                                                                       
  Smoker                                  26.5 ± 8.4                             24.6 ± 6.8                 27.4 ± 7.9                            26.4 ± 8.5                                           0.78      0.86
  Non-smoker                              30.4 ± 12.5                            26.7 ± 10.6                28.4 ± 6.8                            27.7 ± 9.3                                           0.56      0.12
  *VDR* (rs731236)                        TT                                     TC                         CC                                    CC + TC                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  21.5 ± 7.5                             23.5 ± 3.2                 22.5 ± 6.9                            23.1 ± 4.7                                           0.88      0.91
  Non-smoker                              26.6 ± 4.4                             25.1 ± 7.2                 25.5 ± 5.6                            25.4 ± 6.8                                           0.69      0.70
  Controls                                                                                                                                                                                                       
  Smoker                                  29.0 ± 11.4                            22.5 ± 5.6                 29.3 ± 6.7                            27.4 ± 10.2                                          0.87      0.75
  Non-smoker                              26.8 ± 9.7                             28.3 ± 6.0                 27.4 ± 7.1                            27.9 ± 6.7                                           0.75      0.59
  *CYP24A1* (rs6068816)                   CC                                     CT                         TT                                    TT + CT                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  14.7 ± 5.2                             16.3 ± 7.8                 18.7 ± 5.8                            17.4 ± 6.8                                           0.002     0.02
  Non-smoker                              18.4 ± 4.7                             22.4 ± 6.9                 27.2 ± 13.4                           25.6 ± 9.2                                           0.009     0.003
  Controls                                                                                                                                                                                                       
  Smoker                                  15.6 ± 7.8                             17.8 ± 10.3                16.5 ± 6.7                            17.0 ± 7.8                                           0.18      0.12
  Non-smoker                              19.5 ± 6.7                             18.6 ± 8.6                 19.6 ± 6.9                            19.2 ± 7.5                                           0.24      0.35
  *CYP24A1* (rs2244719)                   TT                                     TC                         CC                                    CC + TC                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  26.4 ± 7.9                             27.6 ± 10.9                27.7 ± 6.8                            27.6 ± 5.7                                           0.95      0.85
  Non-smoker                              29.2 ± 11.3                            28.5 ± 9.8                 29.6 ± 8.5                            29.0 ± 8.7                                           0.75      0.84
  Controls                                                                                                                                                                                                       
  Smoker                                  27.0 ± 7.9                             28.5 ± 5.7                 24.6 ± 8.4                            27.7 ± 6.8                                           0.54      0.74
  Non-smoker                              26.7 ± 9.1                             25.7 ± 8.9                 26.1 ± 6.7                            26.0 ± 7.4                                           0.50      0.31
  *CYP24A1* (rs4809960)                   TT                                     TC                         CC                                    CC + TC                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  23.7 ± 5.8                             25.6 ± 9.2                 24.7 ± 7.1                            25.5 ± 6.7                                           0.78      0.67
  Non-smoker                              25.5 ± 5.7                             28.3 ± 7.6                 27.6 ± 8.7                            28.0 ± 8.4                                           0.62      0.56
  Controls                                                                                                                                                                                                       
  Smoker                                  26.8 ± 6.7                             25.2 ± 6.5                 29.7 ± 9.8                            27.8 ± 6.5                                           0.87      0.67
  Non-smoker                              24.7 ± 7.8                             27.8 ± 7.1                 28.3 ± 10.3                           28.1 ± 8.7                                           0.54      0.26
  *CYP24A1* (rs2762939)                   GG                                     GC                         CC                                    CC + GC                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  25.6 ± 4.6                             26.4 ± 6.8                 26.6 ± 9.1                            26.7 ± 7.6                                           0.71      0.65
  Non-smoker                              26.8 ± 5.3                             28.5 ± 7.9                 27.8 ± 7.6                            28.1 ± 7.7                                           0.56      0.73
  Controls                                                                                                                                                                                                       
  Smoker                                  30.3 ± 11.4                            28.6 ± 9.5                 29.8 ± 10.5                           28.8 ± 9.6                                           0.91      0.97
  Non-smoker                              32.3 ± 14.5                            30.4 ± 8.7                 29.5 ± 12.1                           29.9 ± 11.4                                          0.86      0.90
  *CYP24A1* (rs2181874)                   GG                                     GA                         AA                                    AA + GA                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  25.7 ± 6.7                             24.2 ± 9.2                 23.5 ± 10.4                           23.1 ± 8.6                                           0.26      0.17
  Non-smoker                              27.6 ± 4.6                             26.7 ± 7.9                 25.2 ± 6.4                            25.8 ± 6.8                                           0.31      0.12
  Controls                                                                                                                                                                                                       
  Smoker                                  28.0 ± 6.5                             25.6 ± 7.8                 24.6 ± 7.2                            24.4 ± 6.5                                           0.06      0.07
  Non-smoker                              28.5 ± 7.9                             27.8 ± 6.8                 25.4 ± 7.0                            26.4 ± 10.4                                          0.17      0.12
  *CYP24A1* (rs2296241)                   GG                                     GA                         AA                                    AA + GA                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  24.3 ± 11.3                            21.6 ± 10.5                20.6 ± 9.6                            21.4 ± 7.5                                           0.18      0.25
  Non-smoker                              24.8 ± 7.4                             22.7 ± 9.8                 20.5 ± 8.5                            21.8 ± 9.4                                           0.06      0.17
  Controls                                                                                                                                                                                                       
  Smoker                                  24.4 ± 6.5                             22.7 ± 8.3                 23.5 ± 11.4                           24.5 ± 10.7                                          0.44      0.77
  Non-smoker                              26.4 ± 14.7                            25.7 ± 12.1                24.7 ± 10.9                           25.1 ± 11.1                                          0.22      0.25
  *CYP27B1* (rs10877012)                  GG                                     GT                         TT                                    TT + GT                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  26.1 ± 9.5                             28.6 ± 7.8                 30.1 ± 10.3                           28.4 ± 11.4                                          0.87      0.65
  Non-smoker                              28.8 ± 6.4                             27.5 ± 8.9                 29.7 ± 9.4                            28.6 ± 9.1                                           0.76      0.86
  Controls                                                                                                                                                                                                       
  Smoker                                  27.0 ± 7.2                             25.7 ± 8.9                 29.7 ± 6.7                            28.8 ± 8.1                                           0.21      0.45
  Non-smoker                              27.8 ± 9.8                             29.9 ± 7.4                 30.4 ± 7.9                            30.0 ± 7.7                                           0.43      0.28
  *CYP27B1* (rs3782130)                   CC                                     CG                         GG                                    GG + CG                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  24.5 ± 5.6                             26.5 ± 7.5                 26.0 ± 5.8                            26.3 ± 6.1                                           0.87      0.56
  Non-smoker                              27.5 ± 8.5                             29.8 ± 10.6                28.6 ± 7.0                            28.1 ± 9.2                                           0.73      0.96
  Controls                                                                                                                                                                                                       
  Smoker                                  25.4 ± 5.1                             30.2 ± 11.5                27.5 ± 9.8                            28.9 ± 10.8                                          0.13      0.09
  Non-smoker                              27.6 ± 9.6                             27.7 ± 10.6                28.8 ± 7.9                            28.1 ± 10.7                                          0.42      0.12
  *GC* (rs7041)                           TT                                     TG                         GG                                    GG + TG                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  23.9 ± 7.8                             26.5 ± 6.7                 25.3 ± 6.5                            26.1 ± 5.9                                           0.45      0.34
  Non-smoker                              25.1 ± 8.3                             24.7 ± 7.8                 26.2 ± 5.8                            25.7 ± 7.1                                           0.32      0.56
  Controls                                                                                                                                                                                                       
  Smoker                                  28.0 ± 11.8                            28.9 ± 6.8                 29.8 ± 7.9                            29.3 ± 7.4                                           0.91      0.56
  Non-smoker                              28.1 ± 9.5                             28.6 ± 9.4                 29.6 ± 8.1                            29.0 ± 9.2                                           0.83      0.67
  *GC* (rs4588)                           CC                                     CA                         AA                                    AA + CA                                                        
  Cases                                                                                                                                                                                                          
  Smoker                                  24.3 ± 6.1                             26.3 ± 5.9                 27.0 ± 8.3                            26.7 ± 7.4                                           0.43      0.61
  Non-smoker                              25.1 ± 6.0                             27.1 ± 9.4                 27.4 ± 5.7                            27.3 ± 8.7                                           0.85      0.93
  Controls                                                                                                                                                                                                       
  Smoker                                  25.7 ± 3.5                             26.4 ± 5.6                 27.4 ± 7.6                            27.0 ± 6.3                                           0.21      0.34
  Non-smoker                              29.6 ± 8.2                             27.3 ± 8.9                 29.6 ± 11.5                           28.5 ± 10.2                                          0.16      0.56

^a^ Comparing across all three genotypes; ^b^ Comparing the homozygous major genotype to the combination of heterozygous and homozygous minor genotypes.
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###### 

Associations between NSCLC risk and SNPs by smoking status.

  Genotype                Non-Smoker    Smoker                                                        
  ----------------------- ------------- ------------- ------------------- ------------- ------------- -------------------
  *CYP24A1* (rs2181874)                                                                               
  GG + GA                 102 (80.3%)   215 (94.7%)   1.00 (ref)          256 (86.2%)   197 (92.1%)   1.00 (ref)
  AA                      25 (19.7%)    12 (5.3%)     2.14 (1.47--3.43)   41 (13.8%)    17 (7.9%)     3.57 (2.66--4.74)
  *p*                     0.031         0.019                                                         
  *p*-Interaction         0.016                                                                       
  *CYP24A1* (rs6068816)                                                                               
  CC + CT                 91 (71.7%)    158 (74.0%)   1.00 (ref)          282 (94.9%)   182 (85.1%)   1.00 (ref)
  TT                      36 (28.3%)    69 (30.4%)    0.84 (0.65--1.41)   15 (5.1%)     32 (14.9%)    0.43 (0.27--1.02)
  *p*                     0.079         0.006                                                         
  *p*-Interaction         0.038                                                                       
  *VDR* (rs10735810)                                                                                  
  CC + CT                 112 (88.2%)   198 (87.2%)   1.00 (ref)          237 (79.8%)   186 (86.9%)   1.00 (ref)
  TT                      15 (11.8%)    29 (12.8%)    1.16 (0.82--1.34)   60 (20.2%)    28 (13.1%)    1.93 (1.41--2.76)
  *p*                     0.256         0.015                                                         
  *p*-Interaction         0.004                                                                       
  *VDR* (rs1544410)                                                                                   
  GG + GA                 116 (91.3%)   172 (75.8%)   1.00 (ref)          294 (98.9%)   175 (81.8%)   1.00 (ref)
  AA                      11 (8.7%)     55 (24.2%)    0.51 (0.34--1.17)   3 (1.0%)      39 (18.2%)    0.26 (0.20--0.69)
  *p*                     0.002         0.001                                                         
  *p*-Interaction         0.002                                                                       

^a^ Covariates used for adjustment included age, gender, and family history of NSCLC and BMI.
